EV-Based Liquid Biopsy Market by Type, Application, End User

Description

List of Tables

[183 Pages Report] The EV-Based Liquid Biopsy Market size was estimated at USD 409.66 million in 2023 and expected to reach USD 473.12 million in 2024, at a CAGR 15.89% to reach USD 1,150.80 million by 2030.

EV-based liquid biopsy, encompassing the extraction and analysis of extracellular vesicles (EVs) from bodily fluids, represents a pioneering frontier in non-invasive cancer diagnostics and monitoring. EVs, which are lipid-bound particles released from cells, carry a wealth of molecular information, such as DNA, RNA, and proteins, reflective of the health status of their cells of origin. The major factors propelling the use of EV-based liquid biopsies include their non-invasive nature, the potential for early cancer detection, the capability to monitor disease progression and treatment response, and the ability to provide insights into tumor heterogeneity. Nevertheless, this nascent technology faces challenges such as the need for standardized methods for EV isolation and analysis, sensitivity in detecting low-abundance EVs, and the interpretive complexity of the data obtained. Addressing these restraints requires rigorous research to establish uniform protocols, advances in analytical technologies to enhance sensitivity and specificity, and sophisticated bioinformatics tools for data interpretation. The development of point-of-care devices for real-time monitoring, integration with artificial intelligence for predictive analytics, and expansion into other diseases beyond cancer illustrate EV-based liquid biopsy's profound impact on personalized medicine and diagnostic landscapes.

KEY MARKET STATISTICS
Base Year [2023]	USD 409.66 million
Estimated Year [2024]	USD 473.12 million
Forecast Year [2030]	USD 1,150.80 million
CAGR (%)	15.89%

Regional Insights

In the Americas, particularly the United States, there's a high adoption rate of advanced diagnostic solutions, including EV-based liquid biopsies, driven by substantial investments in healthcare R&D and a robust regulatory framework spearheaded by the FDA. This environment fosters a competitive market landscape, with numerous biotech firms and startups pioneering in EV research and diagnostics. The APAC region, led by countries such as China and Japan, is witnessing major growth in the EV-based liquid biopsy sector, attributed to increasing healthcare expenditure, rising patient awareness, and escalating prevalence of cancer. The region's focus is on the use, production, and development of innovative EV-based diagnostics supported by favorable government policies. However, the market here is somewhat fragmented owing to the vast geographical and economic diversities between countries. The EMEA region demonstrates a balanced mix of mature and emerging markets, with Western Europe at the forefront of adopting EV-based liquid biopsy techniques, backed by strong healthcare systems and high awareness about non-invasive diagnostic methods. The Middle Eastern and African markets are gradually picking up pace, with investments flowing in from public and private sectors to enhance healthcare infrastructure and services.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the EV-Based Liquid Biopsy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Prevalence of cancer and need for early intervention
- Increasing preference for non-invasive diagnostic procedures

Market Restraints
- High cost of EV-based liquid biopsy technologies

Market Opportunities
- Advancements in EV-based liquid biopsy procedures
- Favorable government approvals for liquid biopsy

Market Challenges
- Technical complications of performing EV-based liquid biopsy

Market Segmentation Analysis
- Type: Rise of assay kits as a standardized approach crucial for clinical diagnostics
- End User: Adoption of EV-based liquid biopsy in academic and research laboratories for drug development and personalized medicine

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the EV-Based Liquid Biopsy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the EV-Based Liquid Biopsy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio

Quest Diagnostics announces the successful completion of its acquisition of Haystack Oncology. This strategic move enriches Quest's portfolio with Haystack Oncology's minimal-residual disease (MRD) testing technology. Leveraging circulating tumor DNA (ctDNA), this advanced MRD testing technology significantly enhances the early detection capabilities for residual or recurring cancers, offering a transformative approach to guiding therapy choices. Quest Diagnostics plans to integrate this cutting-edge technology into developing novel blood-based laboratory services tailored for solid tumor cancers, marking a significant advancement in cancer diagnosis and treatment. [Published On: 2023-06-21]

Agena Bioscience and nRichDX Announce a Commercial Partnership to Create Solutions for the Extraction and Detection of Liquid Biopsy Analytes

Agena Bioscience has solidified its partnership with nRichDX, transitioning from a technical collaboration to a commercial alliance to promote its products within the research community. This partnership heralds significant advancements by coupling Agena's MassARRAY technology with nRichDX's Revolution Sample Prep System, a combination poised to redefine the landscape of liquid biopsy applications. The Revolution Sample Prep System stands out by consistently achieving higher yield extraction of these elusive variant transcripts from bodily fluids, elevating the MassARRAY platform's sensitivity threshold for detecting rare genetic markers in cancer. [Published On: 2023-04-14]

Mercy BioAnalytics Raises USD 41 Million in Series A Financing to Advance Novel Mercy Halo Liquid Biopsy Platform for Early Cancer Detection

Mercy BioAnalytics, Inc., an innovator in cancer detection through extracellular vesicle-based liquid biopsies, announced the successful closure of a notable USD 41 million in Series A funding. This achievement was led by Novalis LifeSciences and received robust support from a prestigious assembly of investors, including Sozo Ventures, Hatteras Venture Partners, iSelect Fund, American Cancer Society BrightEdge, and Broadway Angels. The investment aims to further the development of Mercy BioAnalytics' Mercy Halo platform, which stands out for its exceptional clinical sensitivity and specificity. [Published On: 2023-04-03]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the EV-Based Liquid Biopsy Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the EV-Based Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Abcam PLC, Agena Bioscience, Agilent Technologies, Inc., ALS Automated Lab Solutions GmbH, ANGLE PLC, Bio-Rad Laboratories, Inc, Bio-Techne Corporation, BioFluidica, Biological Dynamics, Bristol-Myers Squibb, C.H. Boehringer Sohn AG & Co. KG, Clinomics Europe Ltd., Corning Incorporated, ExosomeDx, Horiba Ltd., Illumina, Inc., Lonza Group Ltd., Malvern Panalytical Ltd., Mercy BioAnalytics, Inc., MoBiTec GmbH by BIOZOL Diagnostica Vertrieb GmbH, Mursla Bio, Nanostics Inc., PerkinElmer, Inc., Qiagen N.V., Quest Diagnostics, System Biosciences, LLC, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the EV-Based Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Assay Kits
- Instruments
- Services

Application
- Early Cancer Screening
- Recurrence Monitoring
- Therapy Selection
- Treatment Monitoring

End User
- Academic & Research Institutes
- Clinical Laboratories
- Pharmaceutical & Biotechnology Companies

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-2E76C3E47F69

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of cancer and need for early intervention
  - 5.1.1.2. Increasing preference for non-invasive diagnostic procedures
- 5.1.2. Restraints
  - 5.1.2.1. High cost of EV-based liquid biopsy technologies
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in EV-based liquid biopsy procedures
  - 5.1.3.2. Favorable government approvals for liquid biopsy
- 5.1.4. Challenges
  - 5.1.4.1. Technical complications of performing EV-based liquid biopsy
5.2. Market Segmentation Analysis
- 5.2.1. Type: Rise of assay kits as a standardized approach crucial for clinical diagnostics
- 5.2.2. End User: Adoption of EV-based liquid biopsy in academic and research laboratories for drug development and personalized medicine
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. EV-Based Liquid Biopsy Market, by Type

6.1. Introduction
6.2. Assay Kits
6.3. Instruments
6.4. Services

7. EV-Based Liquid Biopsy Market, by Application

7.1. Introduction
7.2. Early Cancer Screening
7.3. Recurrence Monitoring
7.4. Therapy Selection
7.5. Treatment Monitoring

8. EV-Based Liquid Biopsy Market, by End User

8.1. Introduction
8.2. Academic & Research Institutes
8.3. Clinical Laboratories
8.4. Pharmaceutical & Biotechnology Companies

9. Americas EV-Based Liquid Biopsy Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific EV-Based Liquid Biopsy Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa EV-Based Liquid Biopsy Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Quest Diagnostics Completes Acquisition of Haystack Oncology, Adding Sensitive MRD Liquid Biopsy Technology to Cancer Diagnostics Portfolio
- 12.3.2. Agena Bioscience and nRichDX Announce a Commercial Partnership to Create Solutions for the Extraction and Detection of Liquid Biopsy Analytes
- 12.3.3. Mercy BioAnalytics Raises USD 41 Million in Series A Financing to Advance Novel Mercy Halo Liquid Biopsy Platform for Early Cancer Detection
12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio